27063-93-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2,4-dimethylpyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its reactivity allows for substitution, coupling, and metal complexation reactions, facilitating the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-2,4-dimethylpyridine is utilized as a precursor for the production of various agrochemicals. Its versatility in chemical reactions enables the creation of effective pesticides and other agricultural chemicals that contribute to enhanced crop protection and yield.
Overall, 3-Bromo-2,4-dimethylpyridine's unique chemical properties and reactivity make it an indispensable component in the synthesis of a wide range of chemical products across different industries.

InChI:InChI=1/C7H8BrN/c1-5-3-4-9-6(2)7(5)8/h3-4H,1-2H3

Upstream product

• 108-47-4 2,4-lutidine 
• 29976-20-3 3,5-dibromo-2,4-dimethylpyridine 

Downstream Products

• 1222184-73-7 3-bromopyridine-2,4-dicarboxylic acid 
• 27063-92-9 5-bromo-2,4-dimethyl-pyridine 

Relevant academic research and scientific papers

Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates

Based on structural analysis of the human 2-oxoglutarate (2OG) dependent JMJD2 histone Nε-methyl lysyl demethylase family, 3-substituted pyridine 2,4-dicarboxylic acids were identified as potential inhibitors with possible selectivity over other human 2OG oxygenases. Microwave-assisted palladium-catalysed cross coupling methodology was developed to install a diverse set of substituents on the sterically demanding C-3 position of a pyridine 2,4-dicarboxylate scaffold. The subsequently prepared di-acids were tested for in vitro inhibition of the histone demethylase JMJD2E and another human 2OG oxygenase, prolyl-hydroxylase domain isoform 2 (PHD2, EGLN1). A subset of substitution patterns yielded inhibitors with selectivity for JMJD2E over PHD2, demonstrating that structure-based inhibitor design can enable selective inhibition of histone demethylases over related human 2OG oxygenases.

HISTONE LYSINE DEMETHYLASE INHIBITORS

The invention provides a compound which is an iV-oxalylglycine derivative of formula (I): a hydroxamic acid derivative of formula (II): or a heteroaryl derivative of fomula (III): wherein n; Z1; Z2; Y1; Y2; A; p; X1; X2; m; R4; B; R5; R6; R7; R8; R9; X3; R10; R11 and R12 are as defined herein, or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of the human 2-oxoglutarate-dependant JMJD2 subfamily of histone demethylases, in particular JMJD2E. Such inhibitors are useful in changing the epigenetic state of cells resulting in the inhibition / activation of chromatin remodelling, multiple gene activation / deactivation, and in treating cancer and other conditions characterised by undesirable cellular proliferation, and psychiatric disorders including depression.

Substituted pyridine-2,4-dicarboxylic acid derivatives and medicaments based on these compounds

The invention relates to substituted pyridine-2,4-dicarboxylic acid derivatives of the formula I STR1 in which R1 and R2 have the meanings given. The invention also relates to a process for the preparation of the abovementioned compo

SUBSTITUTED ISOCYTOSINES HAVING HISTAMINE H2-ANTAGONIST ACTIVITY

The compounds are substituted isocytosines which are histamine H 2-antagonists. Two specific compounds of the present inventon are 2-2-(5-methyl-4-imidazolylmethylthio)ethylamino!-5-(3-pyridylmethyl)-4-pyrimi done and 2-2-(3-bromo-2-pyridylmethylthio)ethylamino!-5-(4-pyridylmethyl)-4-pyrimidone .